US EditionCERo announces SCRI as main site for trial of CER-1236 to treat AML
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
CERo announces SCRI as main site for trial of CER-1236 to treat AML
CERo has announced that Sarah Cannon Research Institute (SCRI) will be the main site for its Phase I study of CER-1236 to treat AML.The post CERo announces SCRI as main site for trial of CER-1236 to treat AML appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
